Literature DB >> 9892210

CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Y U Katagiri1, J Sleeman, H Fujii, P Herrlich, H Hotta, K Tanaka, S Chikuma, H Yagita, K Okumura, M Murakami, I Saiki, A F Chambers, T Uede.   

Abstract

The expression of osteopontin (OPN), CD44 variants, and integrins has been correlated with tumorigenesis and metastasis. Here we show that these proteins cooperate to enhance cell motility. First, we demonstrate that several different CD44 variants bind to OPN in an arginine-glycineaspartic acid-independent manner, but that the standard form of CD44 does not. These CD44 variants bind to both the amino- and COOH-terminal portions of OPN independently of the arginine-glycine-aspartic acid sequence, suggesting that multiple domains on OPN can be bound by the CD44 variants. Antibodies directed against the integrin beta1 subunit are able to inhibit this binding. The binding of CD44 variants to OPN is significantly augmented by both anti-CD44s and anti-CD44v antibodies. This augmentation by anti-CD44 antibodies is OPN specific and, again, can be blocked by anti-beta1 antibodies. Finally, we show that OPN binding by CD44 variants/beta1-containing integrins promotes cell spreading, motility, and chemotactic behavior.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892210

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  92 in total

Review 1.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

3.  In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression.

Authors:  Maria Cecilia G Marcondes; Matthew Poling; Debbie D Watry; DeShon Hall; Howard S Fox
Journal:  Cell Immunol       Date:  2008-08-03       Impact factor: 4.868

4.  Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.

Authors:  B M Wittig; R Sabat; P Holzlöhner; E Witte-Händel; K Heilmann; K Witte; J Triebus; A Tzankov; J D Laman; B Bokemeyer; L Terracciano; C Schwärzler; H Kohler; R Volkmer; C Loddenkemper; K Wolk; U Hoffmann; U Günthert
Journal:  Mucosal Immunol       Date:  2017-11-29       Impact factor: 7.313

5.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 6.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

7.  CD44-mediated phagocytosis induces inside-out activation of complement receptor-3 in murine macrophages.

Authors:  Eric Vachon; Raiza Martin; Vivian Kwok; Vera Cherepanov; Chung-Wai Chow; Claire M Doerschuk; Jonathan Plumb; Sergio Grinstein; Gregory P Downey
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

8.  The role of osteopontin in inflammatory processes.

Authors:  Susan Amanda Lund; Cecilia M Giachelli; Marta Scatena
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

9.  Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis.

Authors:  Jiamu Du; Sheng Hou; Chen Zhong; Zheng Lai; Hui Yang; Jianxin Dai; Dapeng Zhang; Hao Wang; Yajun Guo; Jianping Ding
Journal:  J Mol Biol       Date:  2008-07-31       Impact factor: 5.469

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.